A5036756157- Clostridium difficile and Clostridium perfringens research
- Microscopic Colitis
- Enterobacteriaceae and Cronobacter Research
- Viral gastroenteritis research and epidemiology
- Respiratory viral infections research
- Oral Health Pathology and Treatment
- Dental Research and COVID-19
- Dermatology and Skin Diseases
- Oral microbiology and periodontitis research
- Knowledge Management and Sharing
- Streptococcal Infections and Treatments
- Gastrointestinal motility and disorders
- Antimicrobial Resistance in Staphylococcus
- Antibiotic Use and Resistance
- Helicobacter pylori-related gastroenterology studies
- Antibiotic Resistance in Bacteria
Leeds Teaching Hospitals NHS Trust
2015-2020
University of Leeds
2016-2020
Leeds General Infirmary
2016-2018
Background: There are inconsistent data on the risk factors for Clostridium difficile infection (CDI) in literature. Aims: To use two C. case-control study groups to compare hospitalized patients with diarrhea across different countries. Methods: A multi-center group of CDI cases/controls were identified by standardized testing from seven countries prior EUropean, multi-center, prospective bi-annual point prevalence CLostridium Infection Diarrhea (EUCLID). second was a single center Germany...
ABSTRACT Prevention and management of Clostridium difficile infection (CDI) can be improved by rapid reliable diagnostics. The Vidas C. glutamate dehydrogenase assay had performance comparable to that the Quik Chek-60 (overall agreement, 95%) a sensitivity >93%; thus, it is suitable as first test in two-stage algorithms for CDI diagnosis.
Lower Clostridium difficile spore counts in feces from C infection (CDI) patients treated with fidaxomicin versus vancomycin have been observed. We aimed to determine whether environmental contamination is lower compared those vancomycin/metronidazole.The CDI cases were recruited at 4 UK hospitals (Leeds, Bradford, and London [2 centers]). Environmental samples (5 room sites) taken pretreatment 2-3, 4-5, 6-8, 9-12 days of treatment, end treatment (EOT), post-EOT. Fecal collected diagnosis as...
Abstract Background The optimum diagnostic test method for Clostridioides difficile infection (CDI) remains controversial due to variation in accuracy identifying true CDI. This post hoc analysis examined the impact of CDI testing methodology on efficacy outcomes phase 3 MODIFY I/II trials. Methods In (NCT01241552/NCT01513239), participants received bezlotoxumab (10 mg/kg) or placebo during anti-CDI treatment primary/recurrent (rCDI). Using pooled data, initial clinical cure (ICC) and rCDI...